MMP9 is within the 20q13.12 locus and matrix degradation via MMP9 is known to play a key role in the development of AAA, evidenced by the observation of high levels of MMP9 in end-stage disease specimens.41 This is also an important finding given the development of novel pharmacotherapies that target inflammation and matrix degradation pathways such as tofacitinib (a novel Janus kinase inhibitor). This evidence concerns the gene MMP9 and triple-A syndrome.